BNP Paribas Exane升级微芯片为“优异”, 在2025年Q3成果强劲和2026年Q3前景乐观后, 目标为90美元, BNP Paribas Exane upgraded Microchip to "outperform" with a $90 target after strong Q3 2025 results and a positive Q3 2026 outlook.

BNP Paribas Exane将微芯片技术(MCHP)升级为“超效”, 价格目标为90.00美元, Microchip Technology (MCHP) was upgraded to "outperform" by BNP Paribas Exane, with a $90.00 price target, implying 18.11% upside. 据该公司报告,2025年Q3收入为0.35 EPS, 估计增加2美元,收入为11.4亿美元,略高于预期,尽管逐年下降2%。 The company reported Q3 2025 earnings of $0.35 EPS, beating estimates by $0.02, and $1.14 billion in revenue, slightly above expectations, though down 2.0% year-over-year. 它预测2026年3月30日的EPS为0.340至0.400美元。 It projected Q3 2026 EPS of $0.340–$0.400. 该股票的市场上限为411.8亿美元,52周范围为34.13至77.20美元,协商一致的“机动购买”评级为80.82美元,平均目标是80.82美元。 The stock has a market cap of $41.18 billion, a 52-week range of $34.13 to $77.20, and a consensus "Moderate Buy" rating with an average target of $80.82. 机构拥有率为91.51%。 Institutional ownership is 91.51%.